Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Vaderis Therapeutics is a clinical-stage biotechnology company developing targeted therapies for rare vascular diseases.
LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Abivax develops medicines that alter the body's natural immune system mechanisms.
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.
AN2 Therapeutics focuses on modern biomedical and drug development expertise to provide transformational medicines.
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.
Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.
TCG Crossover has invested in 77 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
TCG Crossover's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Pharmaceutical. The firm invests across 13 different industry categories.
Among tracked funding rounds, Mirum Pharmaceuticals received $600.0M in a Post-IPO Debt round. TCG Crossover's total known invested capital is $11.3B.
TCG Crossover's average investment size is $179.8M across its portfolio of 77 companies.
Recent TCG Crossover portfolio additions include Vicebio, Allakos, RayzeBio, Korsana Biosciences, Versanis Bio. These companies were founded in 2020 or later.